AzTrials
AzTrials

Melanoma (Skin)Phase 2NCT00022464

CCI-779 in Treating Patients With Metastatic Melanoma

A Phase 2 study testing temsirolimus in people with Melanoma (Skin), run by City of Hope Medical Center at 21 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic melanoma. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Melanoma (Skin)
What is being tested?
temsirolimus
How many people
Not given
Where
21 sitesin 2 countries
Study dates
Jun 2001to Sep 2005
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed metastatic melanoma that is incurable by surgery, radiotherapy, or limb perfusion
  • Measurable disease
  • At least 20 mm by conventional techniques OR
  • At least 10 mm by spiral CT scan
  • The following are not considered measurable:
  • Bone lesions
  • Leptomeningeal disease
  • Ascites
  • Pleural/pericardial effusion
  • Inflammatory breast disease
  • Lymphangitis cutis/pulmonis
  • Abdominal masses not confirmed and followed by imaging techniques
  • Cystic lesions
  • Progressive disease
  • No prior or concurrent CNS metastasis

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • More than 4 months

Hematopoietic:

  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic:

  • Bilirubin normal
  • AST and ALT no greater than 2.5 times upper limit of normal
  • Cholesterol no greater than 350 mg/dL (lipid-lowering therapy allowed)
  • Triglycerides no greater than 300 mg/dL except for hydroxymethyl-glutaryl-coenzyme A reductase inhibitors

Renal:

  • Creatinine normal OR
  • Creatinine clearance at least 60 mL/min

Cardiovascular:

  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No prior allergic reactions to compounds of similar chemical or biological composition to study drug
  • No ongoing or active infection
  • No seizure disorder
  • No autoimmune disease
  • No psychiatric illness or social situation that would preclude study
  • No other concurrent uncontrolled illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No more than 1 prior adjuvant biological therapy regimen
  • No more than 1 prior biological therapy regimen for advanced disease
  • At least 6 months since prior biological therapy or biochemotherapy and recovered
  • Prior isolated limb perfusion with biological agent allowed if not to sole site of disease

Chemotherapy:

  • See Biologic therapy
  • Prior isolated limb perfusion with chemotherapy allowed if not to sole site of disease
  • No more than 1 prior chemotherapy-containing regimen for advanced disease, regardless of adjuvant therapy
  • May be in addition to 1 prior biologic regimen for advanced disease OR
  • May have had 1 prior biochemotherapy regimen for advanced disease
  • At least 3 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • At least 1 week since prior dexamethasone
  • No concurrent glucocorticosteroid therapy

Radiotherapy:

  • See Disease Characteristics

Surgery:

  • See Disease Characteristics

Other:

  • At least 1 week since prior phenobarbital, phenytoin, carbamazepine, or rifampin
  • At least 3 weeks since other prior agents to treat malignancy
  • At least 3 weeks since prior investigational agents
  • No other concurrent investigational agents
  • No concurrent drugs that are metabolized by or alter the level of cytochrome P450-3A

Trial locations and contacts

21 sites in 2 countries.

21 sites in 2 countries

United States18 sites
  • University of Chicago Cancer Research Center

    Chicago, Illinois, 60637-1470

  • Louis A. Weiss Memorial Hospital

    Chicago, Illinois, 60640

  • Decatur Memorial Hospital Cancer Care Institute

    Decatur, Illinois, 62526

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010-0269

  • Evanston Northwestern Health Care - Evanston Hospital

    Evanston, Illinois, 60201

  • Fort Wayne Medical Oncology and Hematology, Incorporated

    Fort Wayne, Indiana, 46885-5099

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426

  • LaGrange Memorial Hospital

    LaGrange, Illinois, 60525

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California, 90089

  • North Shore University Hospital

    Manhasset, New York, 11030

  • Loyola University Medical Center

    Maywood, Illinois, 60153

  • Weill Medical College of Cornell University

    New York, New York, 10021

  • City of Hope Medical Group

    Pasadena, California, 91105

  • Oncology/Hematology Associates of Central Illinois, P.C.

    Peoria, Illinois, 61602

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104-4283

  • University of California Davis Cancer Center

    Sacramento, California, 95817

  • CCOP - Northern Indiana CR Consortium

    South Bend, Indiana, 46601

  • Central Illinois Hematology Oncology Center

    Springfield, Illinois, 62701

Other trials in United States

Canada3 sites
  • Cancer Care Ontario-Hamilton Regional Cancer Centre

    Hamilton, Ontario, L8V 5C2

  • Cancer Care Ontario-London Regional Cancer Centre

    London, Ontario, N6A 4L6

  • Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9

Other trials in Canada

About this study

Official title: A Phase II Study Of CCI-779 (NSC 683864) In Metastatic Melanoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of CCI-779 in treating patients who have metastatic melanoma.

Read the detailed description

OBJECTIVES:

  • Determine the anti-tumor activity of CCI-779, in terms of progression-free survival, in patients with metastatic melanoma.
  • Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive CCI-779 IV over 30 minutes on day 1. Courses repeat every 7 days in the absence of disease progression or unacceptable toxicity.

Patients are followed for survival.

PROJECTED ACCRUAL: Approximately 40-50 patients will be accrued for this study within 12 months.

Conditions
Melanoma (Skin)
Being tested
temsirolimus
Keywords
stage IV melanoma, recurrent melanoma
Medical subject headings
Melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • temsirolimusDrug

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2003 (estimated)
  2. Study startJun 2001
  3. Primary completionSep 2005
  4. Study completionSep 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
IDs, dates and publications
ClinicalTrials.gov ID
NCT00022464
Sponsor's protocol ID
CDR0000068820
Other IDs
U01CA063265, P30CA033572, CHNMC-PHII-27, CHNMC-IRB-99167, NCI-29
Status last verified
Jun 2015
First submitted
10 Aug 2001
Last updated
8 Jun 2015
Results posted
No

Publications

  • Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005 Sep 1;104(5):1045-8. doi: 10.1002/cncr.21265.

    PubMed 16007689

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing temsirolimus in people with Melanoma (Skin), run by City of Hope Medical Center at 21 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jun 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 21 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00022464, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in